期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

英夫利西单抗在风湿性疾病中的应用进展 被引量：2

Infliximab in the treatment of rheumatic diseases
原文传递
导出
摘要 英夫利西单抗为针对肿瘤坏死因子(TNF)-α的单克隆抗体,主要用于风湿性疾病治疗。本文着重介绍全球英夫利西单抗在类风湿关节炎、强直性脊柱炎、克隆恩病、活动性溃疡性结肠炎、斑块型银屑病及银屑病性关节炎等风湿性疾病中的应用进展。 Infliximab （Remicade）, a monoclonal antibody targeted to tumor necrosis factor （TNF） -α, is mainly used in rheumatic diseases. This review describes the application progress of infliximab in the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn＇s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
作者 程东生 薛勤 汪年松
机构地区 上海交通大学附属第六人民医院肾脏风湿科
出处 《世界临床药物》 CAS 2012年第2期78-82,共5页 World Clinical Drug
关键词 英夫利西单抗 肿瘤坏死因子 风湿性疾病 infliximab tumor necrosis factor rheumatic disease
分类号 R593.2 [医药卫生—内科学] R977 [医药卫生—药品]
  • 相关文献

参考文献11

  • 1Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis [J]. Arthritis Rheum, 1998, 41 (9):1552-1563.
  • 2Elliott MJ, Maini RN, Feldmann M, et al. Randomised double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis [J]. Lancet, 1994, 344 (8930) : 1105-1110.
  • 3Keating GM, Perry CM.Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis [J]. BioDrugs, 2002, 16(2):111-148.
  • 4Zou JX, Braun J, Sieper J. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changesduring treatment [J]. ClinExpRheumatol, 2002, 20 (Suppl 28) : S34-S37.
  • 5Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study [J]. Arthritis Rheum, 2005, 52 (2) : 548-553.
  • 6Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab [J]. Arthritis Rheum, 2000, 43 (6) : 1346-1352.
  • 7Vander Cruyssen B, Durez P, Westhovens R, et al. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity [J]. Arthritis Res Ther, 2010, 12 (3) : R77.
  • 8Maini RN, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-mmour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial[J]. Lancet, 1999, 354 (9194) :1932-1939.
  • 9Targan SR, Hanauer SB, van Deventer S J, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease[J]. N Engl J Med, 1997, 337(15): 1029-1035.
  • 10Maksymowych WE Salonen D, Inman RE), et al. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study [J]. J Rheumatol, 2010, 37 (8): 1728-1734.

同被引文献16

引证文献2

二级引证文献9

世界临床药物
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部